CALCULATE YOUR SIP RETURNS

Indegene Posts 11.4% Revenue Growth in Q1 FY25

14 August 20242 mins read by Angel One
Indegene Limited reported a revenue of ₹6,765 million in Q1 FY25, reflecting an 11.4% growth compared to the same quarter in FY24.
Indegene Posts 11.4% Revenue Growth in Q1 FY25
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Indegene Limited, a leading digital-first commercialisation services company, released its financial results for the quarter ended June 30, 2024.

The company achieved a revenue of ₹6,765 million in Q1 FY25, marking an 11.4% growth compared to Q1 FY24. Additionally, Indegene reported a robust EBITDA growth of 14.5% in Q1 FY25 over the same period last year. The company also successfully became a zero-debt entity. The profit after tax for Q1 FY25 stood at ₹877 million, up from ₹684 million in Q1 FY24.

Commenting on the financial performance for the quarter, the Chairman and CEO of Indegene Limited, Manish Gupta, said, “In Q1FY25, we achieved revenue growth of 11.4% and robust EBITDA growth of 14.5% vs Q1FY24. We continue to see momentum and growth with our largest client and a few of our Top 20 clients, with increased activity and volume levels tracking the larger pipeline of impending new product launches. Based on our conversations with our top clients, we anticipate similar momentum across the industry. Further, compared to last year, our pipeline is healthier, and the quality of conversations with clients is much better, which gives us confidence about driving robust growth in the medium term.”

“Our Q1FY25 EBITDA margin of 19.6% and PAT margin of 13.0% is an improvement of 50 bps and 170 bps vs Q1FY24. Indegene is now a zero-debt company with repayment of loans, and we anticipate the financial leverage to drive stronger PAT growth going forward”, said Suhas Prabhu, CFO, Indegene Limited.

Suhas further added, “Also, we continue to strengthen our technology and automation initiatives, which we believe will have a positive impact on the margin in the future. Further, we anticipate that the EBITDA margin would have a similar trajectory as FY24 with a stronger H2 compared to H1.”

About Indegene Limited

Indegene Limited is a digital-first life sciences commercialisation company that assists biopharmaceutical, emerging biotech, and medical device companies in developing products, bringing them to market, and enhancing their impact throughout the product lifecycle in a more efficient, effective, and modern manner.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.

We're Live on WhatsApp! Join our channel for market insights & updates

Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Send App Link
Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Enjoy ₹0 Account Opening Charges